The rising geriatric population, growing number of surgical procedures, high incidence of hospital-acquired infections, and the commercialization and availability of a wide variety of approved sepsis diagnostic devices are also supporting the growth of this market. However, lack of established reimbursement policies for sepsis and the high cost of automated diagnostic devices are the major factors restraining the growth of this market across the globe.
How much is the Sepsis Diagnostics Market worth?
The sepsis diagnostics market is projected to reach USD 7.39 Billion by 2022 from 6.13 Billion in 2017, at a CAGR of 3.8%. Factors such as the growing number of surgical procedures, influx of novel sepsis diagnostic products, high incidence of hospital-acquired infections, funding for sepsis-related research activities, and the commercialization and availability of a wide variety of approved sepsis diagnostic devices are also supporting the growth of this market. Asia-Pacific is expected to register the highest growth rate during the forecast period, owing to the growing prevalence of sepsis in APAC countries, rising focus of global players in this region, developing healthcare infrastructure, and rising government support for sepsis-related research.
Download PDF Brochure @
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155
Based on technology, the biomarkers segment is expected to register the highest growth rate during the forecast period
Based on technology, the global sepsis diagnostics market is segmented into— microbiology, molecular diagnostics, immunoassay, flow cytometry, microfluidics, and biomarkers. The biomarkers segment is expected to grow at the highest CAGR during the forecast period. The growth of this segment can be attributed to various advantages offered by this technique in the diagnosis of sepsis and growing need for early disease diagnosis.
Based on product, the blood culture media segment accounted for the largest share of the market in 2018
On the basis of products, the global sepsis diagnostics market is segmented into blood culture media, assays & reagents, instruments, and software. In 2018, the blood culture media segment accounted for the largest share of the market owing to the increased use of blood culture media as it is the standard method for diagnosis of sepsis across the globe.
The automated molecular sepsis diagnostics market segment to register higher CAGR during the forecast period
On the basis of methods, the sepsis diagnostics market is categorized into two segments, namely, conventional diagnostics and automated diagnostics. The automated diagnostics segment is expected to grow at the highest CAGR from 2018 to 2023. Accurate detection of positive blood cultures, quick turnaround time, and reduced risk of contamination is contributing to the growth of this segment.
Request for Sample Pages @
https://www.marketsandmarkets.com/requestsampleNew.asp?id=92673155
Asia Pacific is expected to grow at the highest CAGR in the molecular sepsis diagnostics market during the forecast period
This report covers the market across four major geographies, namely, North America, Europe, AsiaPacific, and the Rest of the World (RoW). Of the four geographic regions studied in the report, Asia-Pacific is expected to register the highest growth rate during the forecast period, owing to the growing prevalence of sepsis in APAC countries, rising focus of global players in this region, developing healthcare infrastructure, and rising government support for sepsis-related research.
Geographically, the sepsis diagnostics market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The Asia Pacific is one of the major high growth revenue-generating regions in the sepsis diagnostics market. China, India, and Japan are the major countries responsible for the high growth of this regional market owing to factors such as the increasing number of surgical procedures, improving healthcare infrastructure, and rising number of clinical studies in these emerging countries focusing on the diagnosis of various blood-borne infections including sepsis.
Leading Companies
The major players in the market include bioMérieux (France), Becton, Dickinson, and Company (US), Danaher (US), T2 Biosystems (US), Luminex (US), Roche Diagnostics (Switzerland), Thermo Fisher Scientific (US), Bruker (US), Abbott Laboratories (US), Immunexpress (Australia), Response Biomedical Corp. (Canada), Axis-Shield Diagnostics (UK), CytoSorbents (US), Mitsubishi Chemical Europe (Germany), and EKF Diagnostics Holdings (UK), among others.
For More Information @ https://www.marketsandmarkets.com/PressReleases/sepsis-diagnostic.asp